

Reference Data

Fiscal Year 2019
(April 1, 2019 to March 31, 2020)

Consolidated Earnings

- Consolidated Financial Data p. 1
- Consolidated Balance Sheets p. 2
- Consolidated P/L Statement p. 3
- Consolidated Sales Breakdown by Segment/Category p. 4
- Consolidated Operating Profit by Segment p. 4
- Consolidated Sales -
 - Leading Brands of Self-Medication Operations
 - Sales by Region p. 5
- Consolidated Sales -
 - Leading Products of Prescription Pharmaceutical Operations p. 6
- Capital Expenditure p. 7
- Depreciation and Amortization p. 7
- R&D Expenses p. 7
- Results of Major Consolidated Subsidiary
 - ◆ Taisho Pharmaceutical p. 8
- Major Subsidiaries and Affiliates p. 9
- Shareholders Information p. 10
- Prescription Pharmaceutical Operations:
 - New Drug Development-Taisho Pharmaceutical p. 11
- Status of New Products p. 12

Consolidated Financial Data

(Millions of yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	(Est) March 2021 (FY2020)
Net sales	279,773	280,092	261,551	288,527	289,500
(YOY%)	(-3.6%)	(+0.1%)	(-6.6%)	(+10.3%)	(+0.3%)
Self-Medication operations	179,992	183,996	180,123	220,027	235,900
Prescription Pharmaceutical operations	99,781	96,096	81,428	68,500	53,600
Gross profit on sales*	178,226	182,984	170,163	180,383	180,900
Selling, general and administrative expenses	146,260	146,007	138,951	158,923	160,900
Research and development expenses	21,260	21,150	20,801	22,876	21,200
(% Sales)	(7.6%)	(7.6%)	(8.0%)	(7.9%)	(7.3%)
Advertising expenses	22,087	22,579	20,206	26,046	25,600
Sales promotion expenses	30,079	28,636	27,125	27,440	25,400
Personnel expenses	35,845	35,241	32,491	31,045	32,900
Operating Profit	31,966	36,977	31,211	21,460	20,000
(YOY%)	(+10.7%)	(+15.7%)	(-15.6%)	(-31.2%)	(-6.8%)
Ordinary Profit	38,036	42,140	40,851	25,010	23,000
(YOY%)	(+3.4%)	(+10.8%)	(-3.1%)	(-38.8%)	(-8.0%)
Profit attributable to owners of parent	28,781	31,679	48,593	20,531	13,000
(YOY%)	(+28.1%)	(+10.1%)	(+53.4%)	(-57.7%)	(-36.7%)
Comprehensive income	30,184	36,627	48,027	9,912	-
(YOY%)	(+233.2%)	(+21.3%)	(+31.1%)	(-79.4%)	-
Basic EPS (yen)	360.18	396.54	608.80	257.23	162.89
Diluted EPS (yen)	359.92	396.20	608.22	256.93	162.69
BPS (yen)	8,127.87	8,452.12	8,924.23	8,912.00	8,963.26
Dividend per share (yen)	110.00	110.00	120.00	110.00	100.00
Payout ratio	30.5%	27.7%	19.7%	42.8%	61.4%
Capital expenditure	7,011	4,857	5,259	9,469	20,800
Depreciation and amortization	10,423	10,154	10,073	11,366	15,700
Total assets**	770,685	799,616	821,782	853,051	871,000
Shareholders' equity	665,088	691,318	724,137	741,707	746,000
Return on equity (%)***	4.5%	4.8%	7.0%	2.9%	1.8%
Return on assets (%)***	3.8%	4.0%	6.0%	2.5%	1.5%
Equity ratio (%)**	84.3%	84.4%	86.7%	83.4%	82.1%
Overseas sales	27,529	30,936	30,978	69,500	93,900
Overseas sales ratio (% of total sales)	9.8%	11.0%	11.8%	24.1%	32.4%
Number of employees	6,461	6,340	5,142	9,354	-

* After provision/reversal of reserve for returned unsold goods

** In accordance with the partial modification of the deferred tax accounting standard, a retroactive adjustment was conducted for total assets/equity ratio relating to the fiscal years ended March 2017 to March 2018.

*** Average of the beginning and year-end balance of shareholders' equity / total assets

Consolidated Balance Sheets

(Millions of yen)

	End of FY2018		End of FY2019		change	
	(March 31, 19)	% total	(March 31, 20)	% total		
(Assets)						
I Current assets:	469,781	57.2%	355,623	41.7%	-114,158	
Cash and deposits	282,567		223,814		-58,753	
Notes and accounts receivable-trade	71,286		65,463		-5,822	
Marketable securities	75,900		14,089		-61,811	
Inventories	29,517		43,371		+13,853	
Other	10,509		8,884		-1,624	
II Fixed assets:	352,001	42.8%	497,428	58.3%	+145,426	
(1) Tangible fixed assets:	91,283	(11.1%)	112,555	(13.2%)	+21,272	
Buildings and structures	45,764		56,305		+10,540	
Machinery, equipment and vehicles	5,217		13,480		+8,263	
Land	37,008		37,351		+342	
Other	3,292		5,418		+2,126	
(2) Intangible fixed assets:	24,302	(3.0%)	209,980	(24.6%)	+185,678	
Goodwill	12,534		169,862		+157,328	Effects from the newly consolidated subsidiaries
Sales rights	1,419		690		-729	
Trademarks	5,657		24,620		+18,963	
Software	4,086		6,570		+2,483	
Other	604		8,236		+7,631	
(3) Investments and other assets:	236,416	(28.8%)	174,891	(20.5%)	-61,524	
Investment securities	172,432		145,831		-26,600	
Shares of subsidiaries and affiliates	31,262		11,644		-19,618	
Net defined benefit assets	5,765		4,642		-1,122	
Deferred tax assets	9,365		11,134		+1,768	
Other	17,590		1,638		-15,951	
Total assets	821,782	100.0%	853,051	100.0%	+31,268	
(Liabilities)						
I Current liabilities:	58,453	7.1%	66,456	7.8%	+8,002	
Notes and accounts payable-trade	18,814		18,045		-769	
Accounts payable	14,276		15,743		+1,467	
Accrued income taxes	8,607		5,414		-3,193	
Provision for bonuses	3,123		3,769		+645	
Other	13,630		23,482		+9,852	
II Long-term liabilities:	39,192	4.8%	44,887	5.3%	+5,695	
Net defined benefit liabilities	18,715		20,248		+1,533	
Deferred taxes liabilities	13,530		16,943		+3,413	
Other	6,946		7,695		+748	
Total liabilities	97,645	11.9%	111,343	13.1%	+13,698	
(Net assets)						
I Shareholders' equity	683,025	83.1%	693,958	81.4%	+10,932	
Common stock	30,000		30,000		-	
Capital surplus	14,924		-		-14,924	Impact of the cancellation of treasury stock
Retained earnings	706,742		699,412		-7,329	Profit attributable to owners of parent+20,531, Impact of the cancellation of treasury stock
Treasury stock	-68,641		-35,454		+33,186	Impact of the cancellation of treasury stock
II Accumulated other comprehensive income	29,258	3.6%	17,345	2.0%	-11,913	
Valuation difference on securities	32,017		20,796		-11,221	
Deferred gains or losses on hedges	2,181		-0		-2,181	
Foreign currency translation adjustment	-2,130		-405		+1,725	
Remeasurements of defined benefit plans	-2,809		-3,046		-236	
III Share acquisition rights	687	0.1%	773	0.1%	+86	
IV Non-controlling interests	11,165	1.4%	29,630	3.5%	+18,465	
Total net assets	724,137	88.1%	741,707	86.9%	+17,570	
Total liabilities and net assets	821,782	100.0%	853,051	100.0%	+31,268	

Consolidated P/L Statement

(Millions of yen)

	End of FY2018		End of FY2019		YOY change	
	(March 31, 19)	% total	(March 31, 20)	% total		
Net sales	261,551	100.0%	288,527	100.0%	+26,976	
Cost of sales	91,206	34.9%	108,337	37.5%	+17,131	
Gross profit on sales	170,345	65.1%	180,190	62.5%	+9,845	
Provision for sales returns	182		-192		-375	
Gross profit	170,163	65.1%	180,383	62.5%	+10,220	
Selling, general and administrative expenses	138,951	53.1%	158,923	55.1%	+19,972	
Research and development expenses	20,801		22,876		+2,075	
Advertising expenses	20,206		26,046		+5,840	
Sales promotion expenses	27,125		27,440		+315	
Personnel expenses	32,491		31,045		-1,446	
Other	38,326		51,514		+13,187	Temporary expenses, etc., accompanying corporate combination
Operating Profit	31,211	11.9%	21,460	7.4%	-9,751	
Non-operating income	9,774	3.7%	6,619	2.3%	-3,155	Equity in gains of affiliates -1,416
Non-operating expenses	135	0.1%	3,068	1.1%	+2,933	Foreign exchange losses 2,532
Ordinary Profit	40,851	15.6%	25,010	8.7%	-15,840	
Extraordinary income	42,982	16.4%	6,133	2.1%	-36,848	FY2018: Gain on sales of subsidiaries and affiliates' shares 42,944
Extraordinary losses	19,349	7.4%	832	0.3%	-18,516	FY2018: Early retirement expenses 12,866, impairment loss 2,916
Profit before income taxes and minority interests	64,484	24.7%	30,311	10.5%	-34,172	
Income taxes	14,658	5.6%	8,423	2.9%	-6,234	
Profit	49,825	19.0%	21,887	7.6%	-27,937	
Profit attributable to non-controlling interests	1,231	0.5%	1,356	0.5%	+124	
Profit attributable to owners of parent	48,593	18.6%	20,531	7.1%	-28,062	

Consolidated Sales Breakdown by Segment/Category

(Millions of yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	(Est) March 2021 (FY2020)
Self-Medication operations	179,992	183,996	180,123	220,027	235,900
(YOY%)	(-0.4%)	(+2.2%)	(-2.1%)	(+22.2%)	(+7.2%)
Japan	149,733	150,191	145,983	147,062	138,700
Overseas	27,507	30,921	30,867	69,440	93,900
Other	2,751	2,884	3,272	3,523	3,300
Prescription Pharmaceutical operations	99,781	96,096	81,428	68,500	53,600
(YOY%)	(-8.8%)	(-3.7%)	(-15.3%)	(-15.9%)	(-21.8%)
Ethical drugs	96,126	91,259	79,460	67,022	53,000
Other	3,655	4,837	1,967	1,477	600
Total	279,773	280,092	261,551	288,527	289,500

Consolidated Operating Profit by Segment

(Millions of yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	(Est) March 2021 (FY2020)
Self-Medication operations	30,106	30,162	30,287	19,017	21,800
(YOY%)	(+6.0%)	(+0.2%)	(+0.4%)	(-37.2%)	(+14.6%)
Earnings before the amortization of goodwill and trademarks	34,051	34,151	34,276	27,051	34,400
Prescription Pharmaceutical operations (YOY%)	3,352	8,207	2,685	4,144	300
	(+90.9%)	(+144.8%)	(-67.3%)	(+54.4%)	(-92.8%)
Other*	-1,492	-1,393	-1,760	-1,702	-2,100
(YOY%)	(-)	(-)	(-)	(-)	(-)
Total	31,966	36,977	31,211	21,460	20,000

* The "Other" segment represents the Company (a pure holding company), which is not attributable to any reportable segment.

Consolidated Sales - Leading Brands of Self-Medication Operations & Sales by Region

(Billions of Yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020		(Est) March 2021	
				(FY2019)	YOY	(FY2020)	YOY
Japan	149.7	150.2	146.0	147.1	+0.7%	138.7	-5.7%
<i>Lipovitan</i> series	58.5	54.7	52.0	50.9	-2.2%	46.6	-8.4%
<i>Pabron</i> series	26.3	28.9	28.9	29.8	+2.9%	26.6	-10.9%
<i>RiUP</i> series	16.1	16.5	15.3	14.9	-2.8%	14.3	-3.7%
<i>Biofermin</i> series	8.8	8.6	10.2	10.7	+5.1%	9.9	-8.0%
<i>VICKS</i> series	3.6	4.0	4.0	4.3	+7.8%	3.7	-13.8%
GI treatment series	4.0	3.9	3.7	3.7	+1.2%	3.5	-4.8%
<i>Livita</i> series	3.8	3.5	3.4	3.4	-2.5%	3.2	-5.0%
<i>NARON</i> series	3.4	3.2	3.0	3.1	+2.5%	3.0	-3.5%
<i>Colac</i> series	3.3	3.3	3.0	3.2	+5.6%	3.0	-6.8%
Overseas	27.5	30.9	30.9	69.4	+125.0%	93.9	+35.2%
Asia	24.3	27.2	27.6	42.5	+53.7%	44.6	+5.0%
Europe and America	2.2	2.2	1.9	25.8	-	48.3	+87.5%
Others	2.8	2.9	3.3	3.5	+7.7%	3.3	-6.4%

(Rounded to the nearest hundred-million)

Lipovitan Series: Sales Breakdown

(Billions of Yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020		(Est) March 2021	
				(FY2019)	YOY	(FY2020)	YOY
<i>Lipovitan</i> series	58.5	54.7	52.0	50.9	-2.2%	46.6	-8.4%
<i>Lipovitan D</i>	37.2	35.3	33.4	32.1	-3.6%	28.8	-10.3%
Others	21.3	19.5	18.7	18.7	+0.3%	17.8	-5.2%
(100mL other <i>Lipovitans</i>)	13.5	12.7	12.3	12.5	+1.2%	11.5	-7.5%
(50mL other <i>Lipovitans</i>)	7.7	6.8	6.4	6.3	-1.4%	6.2	-0.7%

(Rounded to the nearest hundred-million)

Consolidated Sales - Leading Products of Prescription Pharmaceutical Operations

(Billions of Yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020		(Est) March 2021	
				(FY2019)	YOY	(FY2020)	YOY
<i>Edirol</i>	22.6	25.4	26.2	27.0	+3.0%	14.4	-46.7%
<i>Lusefi</i>	2.9	5.0	5.6	7.1	+27.0%	9.8	+37.4%
<i>Bonviva</i>	5.9	6.5	6.4	6.6	+3.1%	6.9	+4.8%
<i>LOQOA</i>	1.8	3.1	3.5	3.9	+12.0%	4.0	+2.7%
<i>Biofermin</i>	3.9	4.0	3.9	3.8	-3.5%	4.0	+5.2%
<i>Geninax</i>	5.2	4.4	3.5	3.9	+11.9%	3.1	-21.0%
<i>Clarith</i>	9.3	7.7	5.3	4.3	-20.0%	2.8	-34.4%
<i>Palux</i>	5.4	4.9	3.5	3.1	-11.4%	2.3	-26.8%

(Rounded to the nearest hundred-million)

Consolidated: Capital Expenditure

(Millions of yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	(Est) March 2021 (FY2020)
Total capital expenditure	7,011	4,857	5,259	9,469	20,800
Taisho Pharmaceutical	6,013	4,054	3,974	6,471	10,750
Production department	1,104	1,331	1,061	1,597	1,450
Research department	893	1,084	979	940	1,030
Head Office and the others	4,015	1,638	1,932	3,933	8,270
Other subsidiaries	998	803	1,285	2,998	10,050

Consolidated: Depreciation and Amortization

(Millions of yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	(Est) March 2021 (FY2020)
Depreciation and amortization	10,423	10,154	10,073	11,366	15,700
Cost of sales	3,411	3,085	3,225	4,301	6,200
SGA expenses	7,011	7,068	6,847	7,065	9,500

Consolidated: R&D Expenses

(Millions of yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020 (FY2019)	(Est) March 2021 (FY2020)
Total R&D expenses	21,260	21,150	20,801	22,876	21,200
Self-Medication operations	5,497	5,983	5,353	6,754	7,400
Prescription Pharmaceutical operations	15,763	15,167	15,447	16,121	13,800

Results of Major Consolidated Subsidiaries

Sales and earnings of Taisho Pharmaceutical

(Billions of Yen)

	March 2017 (FY2016)	March 2018 (FY2017)	March 2019 (FY2018)	March 2020		(Est) March 2021	
				(FY2019)	YOY	(FY2020)	YOY
Net Sales	203.1	205.2	192.9	217.5	+12.7%	192.2	-11.6%
Self-Medication	152.0	151.9	147.7	149.2	+1.0%	138.7	-7.0%
Prescription Pharmaceutical	51.1	53.2	45.2	68.3	+51.3%	53.6	-21.6%
Operating profit	23.1	25.9	20.3	19.9	-2.3%	19.7	-0.8%
Ordinary profit	26.5	33.6	27.9	20.9	-25.1%	23.3	+11.6%
Profit	20.1	28.2	11.5	14.9	+29.4%	17.1	+14.9%

(Rounded to the nearest hundred-million)

Major Subsidiaries and Affiliates

(As of March 31, 2020)

Company	Address	Capital	Business	Ownership*
(1) Consolidated subsidiaries				%
Taisho Pharmaceutical Co.,Ltd.	Tokyo, Japan	.000 Yen 29,837,892	SMG PD	100.0
MEJIRO KOSAN Co., Ltd.	Tokyo, Japan	.000 Yen 600,000	SMG	100.0
Taisho Okinawa Co.,Ltd.	Okinawa, Japan	.000 Yen 50,000	SMG	100.0
Taisho M.T.C. Co.,Ltd.	Tokyo, Japan	.000 Yen 400,000	SMG	60.0
Taisho Pharmaceutical Logistics Co.,Ltd.	Saitama, Japan	.000 Yen 30,000	SMG	100.0
Biofermin Pharmaceutical Co., Ltd.	Hyogo, Japan	.000 Yen 1,227,000	SMG PD	63.9
Taisho Pharma Co., Ltd.	Tokyo, Japan	.000 Yen 100,000		100.0
TAISHO ACTIVE HEALTH Co., Ltd.	Tokyo, Japan	.000 Yen 100,000	SMG	55.0
TOKUHON Corporation	Tokyo, Japan	.000 Yen 300,000	SMG PD	100.0
Dr. Program Co., Ltd.	Tokyo, Japan	.000 Yen 251,500	SMG	100.0
Taisho Pharmaceutical (Taiwan) Co.,Ltd.	Taiwan	.000 NT\$ 200,000	SMG	100.0
Taisho Pharmaceutical California Inc.	U.S.A.	.000 US\$ 41,050	SMG	100.0
Taisho Pharmaceuticals (Philippines), Inc.	Philippines	.000 Peso 18,900	SMG	100.0
Taisho Co.,Ltd. Shanghai	China	.000 CNY 132,621	SMG	100.0
Taisho Vietnam Co.,Ltd.	Vietnam	.000 VND 170,754,300	SMG	100.0
Taisho Pharmaceutical (H.K.) Ltd.	China	.000 HK\$ 165,300	SMG	100.0
Osotspa Taisho Pharmaceutical Co., Ltd.	Thailand	.000 THB 100,000	SMG	60.0
Taisho Pharmaceutical R&D Inc.	U.S.A.	.000 US\$ 4,000	PD	100.0
PT. Taisho Pharmaceutical Indonesia Tbk	Indonesia	.000 rupiah 10,240,000	SMG	98.6
Taisho Pharmaceutical Singapore Private Limited	Singapore	.000 US\$ 1,365	SMG	100.0
Hoepharm Holdings Sdn.Bhd.	Malaysia	.000 MYR 32,380	SMG	100.0
Compañía Internacional de Comercio, S.A.P.I. de C.V.	Mexico	.000 MXN 122,467	SMG	100.0
Duoc Hau Giang Pharmaceutical JSC	Vietnam	.000 VND 1,307,460,710	SMG	51.0
UPSA SAS	France	.000 EUR 852,103	SMG	100.0
(2) Equity accounting method				
Yomeishu Seizo Co., Ltd.	Tokyo, Japan	.000 Yen 1,650,000	SMG	24.0

SMG=Self-Medication operations PD=Prescription Pharmaceutical operations

*Ownership: including the portion of indirect ownership

Shareholders Information (as of end of March 2020)

Major Shareholders

(Thousands of Shares)

Shareholders	Number of shares	% of total
The Uehara Memorial Foundation	15,000	18.78%
Shoji Uehara	7,774	9.73%
Uehara Museum	3,900	4.88%
Sumitomo Mitsui Banking Corp.	3,000	3.76%
MUFG Bank, Ltd.	3,000	3.76%
The Master Trust Bank of Japan, Ltd. (Trust account)	2,406	3.01%
Akira Uehara	2,143	2.68%
Japan Trustee Services Bank, Ltd. (Trust account)	1,782	2.23%
Kajima Corporation	1,650	2.07%
Japan Trustee Services Bank, Ltd. (Sumitomo Mitsui Trust Bank, Limited ReTrust Account/ Sumitomo Chemical Company, Limited Employee Pension Trust Account)	1,530	1.92%

Shares less than one thousand are rounded down.

Treasury stock of 5,256 thousand shares are excluded from the above as these shares do not have voting rights.

The shareholding ratio is calculated excluding treasury stock. (Rounded to the nearest second decimal place)

Distribution of Ownership Among Shareholders

	% of total
Financial Institutions	21.07%
Financial Instruments Firms	0.62%
Other companies	39.14%
Foreign Companies	13.60%
Individuals and Others	25.57%
Total	100.00%

The shareholder composition is calculated excluding treasury stock of 5,256 thousand shares.

Prescription Pharmaceutical Operations: New Drug Development - Taisho Pharmaceutical

As of May 14, 2020

In Japan

Phase 3

TS-152 (Injection)

< Application	> Rheumatoid arthritis
< Development	> In-license (Licensor: Ablynx)
< Description	> Anti-TNF(Tumor Necrosis Factor)- α antibody
< Remarks	> Generic name: Ozoralizumab

Phase 2

TS-142 (Oral)

< Application	> Insomnia
< Development	> In-house

Overseas

Phase 2

TS-121 (Oral)

< Application	> Depression
< Development	> In-house

Phase 1

TS-134 (Oral)

< Target disease	> Schizophrenia
< In-house/Licensed-in	> In-house

TS-161 (Oral)

< Target disease	> Depression
< In-house/Licensed-in	> In-house

Launch of New Products

As of May 14, 2020

New Products Since FY2019 3Q Earnings Announcement (Feb 14, 2020)

Self-Medication Operations

Lipovitan D : Hayabusa 2 Space Probe Supporters Limited-Edition Bottle (mail order)

- < Description > Limited-edition bottle launched in the hope that the Hayabusa 2 space probe will successfully complete its mission of returning a capsule containing samples from the asteroid Ryugu to Earth in November-December 2020. Bottle comes in five designs: four depicting Hayabusa 2 and one depicting the first spacecraft Hayabusa.
- < Launch > Feb 2020

ALFE beauty conc (Drink type)/ ALFE beauty conc (Powder type)

- < Description > Concentrated beauty food for women who want to shine. Contains 5,000 mg of collagen. Two types available: a patented drink type combining collagen with iron and a powder type in stick packaging which can be taken as is, without water.
- < Launch > Mar 2020

RAIZIN HARD GINGER / RAIZIN FRUITY THUNDER

- < Description > Japan's first triple zero (zero caffeine, zero calorie, zero sugar) carbonated energy drink to contain enXtra, a new caffeine alternative.
- < Launch > Mar 2020

Purinecare Tablets

- < Description > Food with Functional Claims (FFC) containing functional ingredient Anserine for people with high uric acid levels. Product released under the Livita brand of health foods which includes powders, tablets and other products to meet diverse needs according to lifestyle preferences. *Uric acid level at 5.5~7.0mg/dL
- < Launch > Mar 2020

Glucocare Tablets

- < Description > Contains Naringin, a functional ingredient which lowers fasting blood glucose. Food for people concerned about their fasting blood glucose level. Product released under the Livita brand of health foods which includes powders, tablets and other products to meet diverse needs according to lifestyle preferences.
- < Launch > Mar 2020

AdryS Essense Glow Mask (mail order)

- < Description > Sheet mask that hydrates dry skin and makes skin glow. Sheet with a three-layer structure which is filled with exclusive AdryS skincare ingredients and which adheres closely to the skin surface to increase its penetrating power. Recommended as special hydrating skincare which should be applied before bed.
- < Launch > Mar 2020
-

Launch of New Products

As of May 14, 2020

New Products Since FY2019 3Q Earnings Announcement (Feb 14, 2020)

Self-Medication Operations

Tablets for people concerned about their fasting blood glucose level (mail order)

- < Description > Japan's first Food with Functional Claims (FFC) dietary supplement containing Naringin, a functional ingredient which lowers fasting blood glucose. Tablets for people concerned about their fasting blood glucose levels sold exclusively through the Company's online shop Taisho Pharmaceutical Direct.
- < Launch > Mar 2020
-

Lipovitan JELLY

- < Description > Contain maltodextrin, a carbohydrate that is rapidly digested and absorbed, vitamins B1, B2 and B6, citric acid, royal jelly and other nutrients. Pouch-type jelly drink recommended for people looking for an easy way to boost their energy levels.
- < Launch > Apr 2020
-

RiUP X5 Plus NEO

- < Description > Contains glycyrrhetic acid, diphenhydramine hydrochloride and hinokitiol in addition to the formulation of RiUP-X5-PLUS-Lotion. Fully demonstrates minoxidil's positive and intrinsic effect on hair growth through transformation of the scalp environment by the other active ingredients to encourage hair growth.
- < Launch > Apr 2020
-

RiUP SCALP SHAMPOO

- < Description > Deep cleansing ingredient (amino acid surfactant) removes sebum buildup, while active ingredients piroctone olamine and dipotassium glycyrrhizate prevent dandruff and itchy scalp.
- < Launch > Apr 2020
-

RiUP HAIR CONDITIONER

- < Description > A comforting and refreshing conditioner which leaves hair easy to comb and soft, while active ingredients piroctone olamine and dipotassium glycyrrhizate prevent dandruff and itchy scalp.
- < Launch > Apr 2020
-

RiUP SMOOTH RINSE IN SHAMPOO

- < Description > Deep cleansing ingredient (amino acid surfactant) removes sebum buildup, leaving hair feeling soft and freshly washed but not overly squeaky and stripped.
- < Launch > Apr 2020
-

Launch of New Products

As of May 14, 2020

New Products Since FY2019 3Q Earnings Announcement (Feb 14, 2020)

Self-Medication Operations

RiUP MOIST SCALP SHMPOO

< Description > Provides just the right amount of hydration to the scalp for healthier hair. Contains seaweed extract, ginseng extract, hinokitiol, and tocopherol acetate (moisturizer). Pinpoint spray prevents dripping.

< Launch > Apr 2020

Lipovitan D: Japanese professional baseball teams bottle (mail order)

< Description > Limited-edition bottle featuring the mascot characters of each baseball team on the Lipovitan D label. Bottle comes in four designs for each of the 11 baseball teams.

< Launch > Apr 2020

AdryS Overnight Gel

< Description > Night gel applied before bed to generously hydrate skin that has been dried out during the day by UV rays and air-conditioning. Item that can easily be integrated in a skin care regimen.

< Launch > Apr 2020

RIUPENERGY MEDICATED SCALP SHAMPOO / MEDICATED PACK CONDITIONER

< Description > Scalp care series for men aimed at invigorating the scalp. Contains dipotassium glycyrrhizate (anti-inflammatory ingredient), sanguisorba-officinalis and ginkgo biloba extract (moisturizing ingredient). Launched of renewed series with improved texture and fragrance.

< Launch > Apr 2020

Tablets for people concerned about their uric acid level (mail order)

< Description > Food with Functional Claims (FFC) containing functional ingredient Anserine for people with high uric acid levels. Tablets for people concerned about their uric acid level sold exclusively through the Company's online shop Taisho Pharmaceutical Direct. *Uric acid level at 5.5~7.0mg/dL

< Launch > Apr 2020

ROYAL JELLY PLACENTA (mail order)

< Description > Rich, full-flavored premium drink containing 1,000 mg of fresh royal jelly, 200mg of placenta and other carefully selected ingredients. For those wanting to feel supple and full of life every day and those wanting to stay fit and healthy however old they are.

< Launch > Apr 2020

Launch of New Products

As of May 14, 2020

New Products Since FY2019 3Q Earnings Announcement (Feb 14, 2020)

Self-Medication Operations

Choles & Middlecare Capsule W

< Description > Supplement-type food with functional claims (FFC) containing lycopene, a functional ingredient which lowers LDL (bad) cholesterol, as well as DHA and EPA, functional ingredients which lower triglyceride levels. For people concerned about their cholesterol and triglyceride levels.

< Launch > May 2020
